TrilliumBiO Collaborates with The LAM Foundation to Boost LAM Understanding and Education

TrilliumBiO and The LAM Foundation Join Forces to Improve LAM Awareness and Education

In an important collaborative effort, TrilliumBiO, a pioneer in precision diagnostics and biomarker discovery, has partnered with The LAM Foundation, the premier organization in research, advocacy, and support for lymphangioleiomyomatosis (LAM). This partnership aims to enhance the recognition and understanding of LAM, which is a rare progressive lung disease predominantly affecting women.

LAM is characterized by the unusual growth of smooth muscle cells, particularly in the lungs and lymphatic system, leading to significant health problems including diminishing lung function, fluid accumulation in the chest and abdomen, as well as benign tumors in the kidneys. Unfortunately, LAM is estimated to impact 3 to 7 women per million, making awareness and timely diagnosis critical.

Laura Vivian, the CEO of TrilliumBiO, emphasized the importance of addressing the challenges faced by LAM patients. "Patients often endure years of uncertainty while seeking a correct diagnosis," she stated. She noted that the aim of this partnership is to bring greater awareness, refine diagnostic routes, and support the therapeutic development process to achieve improved health outcomes for patients suffering from this condition.

LAM frequently goes unrecognized or is misdiagnosed because of its nonspecific symptoms, which overlap with those of more common respiratory issues. Typically, women experience symptoms for about three to five years, often undergoing multiple occurrences of pneumothorax before receiving accurate diagnoses. To facilitate earlier identification of this ailment, TrilliumBiO has rolled out LAMair™, a VEGF-D (vascular endothelial growth factor D) blood test that is now accessible to healthcare professionals and patients across the country.

Patti Tuomey, Executive Director of The LAM Foundation, expressed the significance of their collaboration, stating, "This partnership enhances our mutual commitment to ensure every individual diagnosed with LAM receives an accurate diagnosis and prompt access to necessary care." She highlighted that increasing awareness among healthcare providers and broadening access to validated diagnostic tools play crucial roles in improving outcomes for the LAM patient community.

Continuing in this joint endeavor, TrilliumBiO and The LAM Foundation plan to focus on educational initiatives. These will include resources designed to assist clinicians in interpreting diagnostic findings, developing supportive materials for patients upon receiving their test results, and conducting programs aimed at raising awareness about LAM among healthcare professionals.

Through these collaborative efforts, both organizations aspire to empower patients, provide essential tools to healthcare providers, and expedite scientific understanding of LAM. To learn more about LAM, diagnostic pathways, and available testing options, visit The LAM Foundation's website. Additionally, for information regarding the LAMair™ test, prospective users can reach out to TrilliumBiO.

In conclusion, this partnership marks a significant step forward in the realm of LAM awareness. With ongoing collaborative efforts focused on education and accessible diagnostic tools, TrilliumBiO and The LAM Foundation are committed to making an impactful difference in the lives of individuals affected by this challenging condition.

For further details on TrilliumBiO, visit www.TrilliumBiO.com. To connect with The LAM Foundation, go to www.thelamfoundation.org for extensive resources and support options.